Industry
Biotechnology
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 8:13 pm
Portfolio Pulse from Benzinga Insights
May 20, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
May 16, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 9:05 pm
Portfolio Pulse from Benzinga Newsdesk
March 21, 2024 | 9:14 pm
Portfolio Pulse from Benzinga Insights
March 19, 2024 | 9:34 pm
Portfolio Pulse from Benzinga Insights
March 08, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Insights
February 09, 2024 | 9:31 pm
Portfolio Pulse from Benzinga Insights
January 23, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Newsdesk
November 10, 2023 | 6:03 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.